Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) Compared to Placebo in Migraine Prevention

PHASE3CompletedINTERVENTIONAL
Enrollment

577

Participants

Timeline

Start Date

July 20, 2015

Primary Completion Date

July 11, 2016

Study Completion Date

March 20, 2017

Conditions
Migraine
Interventions
DRUG

Erenumab

Administered once a month by subcutaneous injection

DRUG

Placebo

Administered once a month by subcutaneous injection

Trial Locations (76)

1205

Research Site, Geneva

2502

Research Site, Biel

2600

Research Site, Glostrup Municipality

2750

Research Site, Ballerup Municipality

5330

Research Site, Bad Zurzach

6903

Research Site, Lugano

7100

Research Site, Vejle

8702

Research Site, Zollikon

9000

Research Site, Aalborg

9007

Research Site, Sankt Gallen

11521

Research Site, Athens

11525

Research Site, Athens

14221

Research Site, Williamsville

15706

Research Site, Santiago de Compostela

16675

Research Site, Athens

19114

Research Site, Philadelphia

21208

Research Site, Baltimore

23454

Research Site, Virginia Beach

27103

Research Site, Winston-Salem

28040

Research Site, Madrid

28806

Research Site, Asheville

29464

Research Site, Mt. Pleasant

30342

Research Site, Atlanta

32216

Research Site, Jacksonville

32765

Research Site, Oviedo

32806

Research Site, Orlando

33021

Research Site, Hollywood

33076

Research Site, Bordeaux

33410

Research Site, Palm Beach Gardens

35216

Research Site, Birmingham

37421

Research Site, Chattanooga

39008

Research Site, Santander

40513

Research Site, Lexington

45245

Research Site, Cincinnati

46010

Research Site, Valencia

46026

Research Site, Valencia

46256

Research Site, Indianapolis

47005

Research Site, Valladolid

48104

Research Site, Ann Arbor

49009

Research Site, Kalamazoo

50009

Research Site, Zaragoza

54645

Research Site, Thessaloniki

60031

Research Site, Gurnee

66214

Research Site, Lenexa

73112

Research Site, Oklahoma City

74374

Research Site, Pringy

75010

Research Site, Paris

75014

Research Site, Paris

75214

Research Site, Dallas

78759

Research Site, Austin

80907

Research Site, Colorado Springs

84121

Research Site, Salt Lake City

85018

Research Site, Phoenix

87102

Research Site, Albuquerque

90230

Research Site, Culver City

90404

Research Site, Santa Monica

90806

Research Site, Long Beach

92103

Research Site, San Diego

94598

Research Site, Walnut Creek

95821

Research Site, Sacramento

98105

Research Site, Seattle

119435

Research Site, Moscow

121467

Research Site, Moscow

197022

Research Site, Saint Petersburg

450083

Research Site, Ufa

630091

Research Site, Novosibirsk

06824

Research Site, Fairfield

02131

Research Site, Boston

08540

Research Site, Princeton

02886

Research Site, Warwick

06003

Research Site, Nice

2720-276

Research Site, Amadora

1500-650

Research Site, Lisbon

1649-035

Research Site, Lisbon

2560-280

Research Site, Torres Vedras

08035

Research Site, Barcelona

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Amgen

INDUSTRY